– Mula J, Chiara F, Manca A, Palermiti A, Maiese D, Cusato J, Simiele M, De Rosa FG, Di Perri G, De Nicolò A,
D’Avolio A. Analytical validation of a novel UHPLC-MS/MS method for 19 antibiotics quantification in
plasma: Implementation in a LC-MS/MS Kit. Biomed Pharmacother.

2023 Jul;163:114790. doi: 10.1016/j.biopha.2023.114790. Epub 2023 Apr 29. PMID: 37126927.

– Corcione S, Vita D, De Nicolò A, Scabini S, Mornese Pinna S, Cusato J, Mangiapia M, D’Avolio A, De Rosa
FG. Pharmacokinetics and pharmacogenetics of high-dosage tedizolid for disseminated nocardiosis in a lung
transplant patient. J Antimicrob Chemother.

2023 Dec 1;78(12):3003-3004. doi: 10.1093/jac/dkad299. PMID: 37788983.

– Funiciello E, Mula J, Mignone F, Silvestro E, Ragazzi P, Pilloni G, Costa C, D’Avolio A, Garazzino S. Plasmatic
and CSF concentrations of cefiderocol in an infant with extensively drug-resistant Pseudomonas aeruginosa
meningoencephalitis. J Antimicrob Chemother.

2023 Nov 6;78(11):2776-2778. doi: 10.1093/jac/dkad277. PMID: 37671818.

– Mornese Pinna S, Corcione S, De Nicolò A, Montrucchio G, Scabini S, Vita D, De Benedetto I, Lupia T, Mula
J, Di Perri G, D’Avolio A, De Rosa FG. Pharmacokinetic of Cefiderocol in Critically Ill Patients Receiving Renal
Replacement Therapy: A Case Series. Antibiotics (Basel).

2022 Dec 16;11(12):1830. doi: 10.3390/antibiotics11121830. PMID: 36551485; PMCID: PMC9774561.

– Venuti F, Gaviraghi A, De Nicolò A, Stroffolini G, Longo BM, Di Vincenzo A, Ranzani FA, Quaranta M,
Romano F, Catellani E, Marchiaro C, Cinnirella G, D’Avolio A, Bonora S, Calcagno A. Real-Life Experience of
Continuously Infused Ceftolozane/Tazobactam in Patients with Bronchiectasis and Multidrug-Resistant
Pseudomonas aeruginosa Infection in the Outpatient Setting. Antibiotics (Basel).

2023 Jul 21;12(7):1214. doi: 10.3390/antibiotics12071214. PMID: 37508309; PMCID: PMC10376517.

– Boni S, Antonucci M, Manca A, Nicolò A, Martinelli L, Artioli S, Pacini G, Di Perri G, D’Avolio A. Ceftobiprole
and daptomycin concentrations in valve tissue in a patient with mitralic native valve endocarditis. J
Chemother.

2022 Oct;34(6):416-418. doi: 10.1080/1120009X.2022.2068850. Epub 2022 Apr 28. PMID:
35484923.

– De Nicolò A, Stroffolini G, Antonucci M, Mula J, De Vivo ED, Cusato J, Palermiti A, Cariti G, Di Perri G,
Corcione S, De Rosa FG, D’Avolio A. Long-Term Pharmacokinetics of Dalbavancin in ABSSSI and
Osteoarticular Settings: A Real-Life Outpatient Context. Biomedicines.

2021 Sep 22;9(10):1288. doi: 10.3390/biomedicines9101288. PMID: 34680409; PMCID: PMC8533485.

– Stroffolini G, De Nicolò A, Gaviraghi A, Mula J, Cariti G, Scabini S, Manca A, Cusato J, Corcione S, Bonora S,
Di Perri G, De Rosa FG, D’Avolio A. Clinical Effectiveness and Pharmacokinetics of Dalbavancin in Treatment-
Experienced Patients with Skin, Osteoarticular, or Vascular Infections. Pharmaceutics.

2022 Sep 6;14(9):1882. doi:10.3390/pharmaceutics14091882. PMID: 36145630; PMCID: PMC9501058.